About ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States.
Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers.
It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor.
The company was incorporated in 2014 and is headquartered in South San Francisco, California.